中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
15期
404-405
,共2页
奥沙利铂%吡柔比星%氟尿嘧啶%晚期肝癌%疗效
奧沙利鉑%吡柔比星%氟尿嘧啶%晚期肝癌%療效
오사리박%필유비성%불뇨밀정%만기간암%료효
Oxaliplatin%Pirarubicin%Fluorouracil%Advanced liver cancer%Efficacy
目的观察联合化疗治疗晚期肝癌的临床疗效及安全性。方法选取我院自2009年1月至2012年10月收治的40例晚期原发性肝癌患者作为研究对象,给予奥沙利铂、吡柔比星及氟尿嘧啶联合化疗,观察临床治疗效果及毒副反应情况。结果40例患者CR 2例,PR 13例,SD 15例,PD 10例,临床总有效率为37.5%。初治9例和复治21例患者的总有效率比较无明显差异(χ2=1.052,P>0.05)。主要毒副反应包括白细胞下降13例(32.5%),贫血2例(5.0%),血小板减少5例(12.5%),恶心呕吐6例(15.0%)。结论应用奥沙利铂为主的联合化疗方案治疗晚期原发性肝癌疗效较好,毒副反应较少,对改善患者预后具有重要价值。
目的觀察聯閤化療治療晚期肝癌的臨床療效及安全性。方法選取我院自2009年1月至2012年10月收治的40例晚期原髮性肝癌患者作為研究對象,給予奧沙利鉑、吡柔比星及氟尿嘧啶聯閤化療,觀察臨床治療效果及毒副反應情況。結果40例患者CR 2例,PR 13例,SD 15例,PD 10例,臨床總有效率為37.5%。初治9例和複治21例患者的總有效率比較無明顯差異(χ2=1.052,P>0.05)。主要毒副反應包括白細胞下降13例(32.5%),貧血2例(5.0%),血小闆減少5例(12.5%),噁心嘔吐6例(15.0%)。結論應用奧沙利鉑為主的聯閤化療方案治療晚期原髮性肝癌療效較好,毒副反應較少,對改善患者預後具有重要價值。
목적관찰연합화료치료만기간암적림상료효급안전성。방법선취아원자2009년1월지2012년10월수치적40례만기원발성간암환자작위연구대상,급여오사리박、필유비성급불뇨밀정연합화료,관찰림상치료효과급독부반응정황。결과40례환자CR 2례,PR 13례,SD 15례,PD 10례,림상총유효솔위37.5%。초치9례화복치21례환자적총유효솔비교무명현차이(χ2=1.052,P>0.05)。주요독부반응포괄백세포하강13례(32.5%),빈혈2례(5.0%),혈소판감소5례(12.5%),악심구토6례(15.0%)。결론응용오사리박위주적연합화료방안치료만기원발성간암료효교호,독부반응교소,대개선환자예후구유중요개치。
Objective To observe the combination chemotherapy in the treatment of advanced hepatocellular carcinoma clinical efficacy and safety. Methods Our hospital from January 2009 to October 2012 admitted 40 patients with advanced primary liver cancer patients as research subjects, given oxaliplatin pirarubicin Star and fluorouracil combination chemotherapy, observe the clinical therapeutic effect and toxicity side effects. Results 40 patients with CR, PR 13, SD 15, PD 10, the clinical total effective rate of 37.5%. Initial treatment of 21 patients in nine cases and retreatment total effective rate was no significant difference (χ2=1.052, P>0.05). The major toxicities including leukopenia in 13 cases (32.5%), anemia in 2 cases (5.0%), thrombocytopenia (12.5%), and nausea and vomiting in 6 cases (15.0%). Conclusion Oxaliplatin-based chemotherapy in the treatment of advanced primary liver cancer better efficacy, less toxicity and has important value to improve the prognosis of patients.